Aptose Biosciences (TSE:APS) Shares Cross Above 50-Day Moving Average – Time to Sell?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO)’s stock price passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$1.96 and traded as high as C$2.32. Aptose Biosciences shares last traded at C$2.30, with a volume of 3,301 shares trading hands.

Analysts Set New Price Targets

Separately, Alliance Global Partners cut shares of Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. One research analyst has rated the stock with a Hold rating, According to MarketBeat, the company has a consensus rating of “Hold”.

Aptose Biosciences Trading Up 1.8%

The company has a current ratio of 1.05, a quick ratio of 5.41 and a debt-to-equity ratio of -117.37. The firm has a market cap of C$5.87 million, a PE ratio of 3.33 and a beta of -0.41. The business has a fifty day moving average price of C$1.96 and a 200 day moving average price of C$1.88.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last posted its earnings results on Thursday, November 13th. The biotechnology company reported C($2.01) earnings per share for the quarter. Analysts forecast that Aptose Biosciences Inc. will post -0.59 EPS for the current year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.